Oncoinvent ASA logo

Oncoinvent ASA

Innovations for better cancer care

47 employees · est. 2010 · Oslo, Norway

VS
Vaccentis logo

Vaccentis

VACCENTIS FOCUSES ON DEVELOPING IMMUNO-ONCOLOGY VACCINES UTILISING ITS AUTOLOGOUS TUMOUR VACCINE TECHNOLOGY PLATFORM

5 employees · est. 2006 · Zurich, Switzerland

Vaccentis is the older company (2010 vs 2006); Oncoinvent ASA is the larger of the two.

Side-by-Side Comparison

Oncoinvent ASA Vaccentis
Founded
2010 2006 older
Headquarters
Oslo, Norway Zurich, Switzerland
Employees
47 larger 5
Industry
Biotechnology, Life Sciences Health Care
Funding Stage
Series Unknown Not tracked yet
Total Funding
$281.00M Not tracked yet
Funding Rounds
3 Not tracked yet
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Oncoinvent, Radiopharmaceuticals, Radspherin, Alpha-emitting Radionuclides, Cancer Treatment, Clinical Stage Company, Metastatic Cancers, Radiotherapeutic Products, Radioimmunotherapeutic Products, Solid Cancers, Clinical Trials, Oslo, Laboratory Facilities, CGMP Immunotherapy, Cancer Vaccines, Oncology, Tumor Vaccine Technology, Autoimmune Oncology, Renal Cell Carcinoma, Metastatic Cancer Treatment, Clinical Research, Patient-Specific Medicines, Evidence-Based Medicine, Medical Product Development, Natural Medicine, Biopharmaceuticals
Website
oncoinvent.com vaccentis.com
Oncoinvent ASA logo

About Oncoinvent ASA

Oncoinvent AS is a biotechnology startup based in Norway that was founded in 2010. The company's slogan, "Innovations for better cancer care," encapsulates its mission to develop new and innovative radiopharmaceutical products for improved treatment options for cancer patients. Its lead product cand...

Vaccentis logo

About Vaccentis

Vaccentis is a health care startup with a focus on developing immuno-oncology vaccines utilizing its autologous tumor vaccine technology platform. The company was founded in 2006 and is currently in the late stage development of an autologous tumor vaccine for Renal Cell Carcinoma. Their medical div...

We will tell you when either one moves

BounceWatch watches Oncoinvent ASA and Vaccentis for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Oncoinvent ASA and Vaccentis — by email.

Frequently Asked Questions

Oncoinvent ASA — Innovations for better cancer care . Vaccentis — VACCENTIS FOCUSES ON DEVELOPING IMMUNO-ONCOLOGY VACCINES UTILISING ITS AUTOLOGOUS TUMOUR VACCINE TECHNOLOGY PLATFORM. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Oncoinvent ASA has raised $281.00M while Vaccentis has raised undisclosed funding.
Oncoinvent ASA and Vaccentis operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Oncoinvent ASA with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Oncoinvent ASA on 11 Sep 2024, and Vaccentis on 17 Nov 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy